The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
Open accessAbstract
Background and objectives: few studies have reported the drug retention rate (DRR) of biologic drugs in juvenile idiopathic arthritis (JIA), and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on systemic JIA (sJIA). This study aims to describe IL-1 inhibitors DRR and evaluate predictive factors of drug survival based on data from a real-world setting concerning sJIA. Methods: Medical records from sJIA patients treated with anakinra (ANA) and canakinumab (CAN) were retrospectively analyzed from 15 Italian tertiary referral centers. Results: Seventy seven patients were enrolled for a total of 86 treatment courses. The cumulative retention rate of the IL-1 inhibitors at 12-, 24-, 48- and 60-months of follow-up was 79.9%, 59.5%, 53.5% and 53.5% respectively, without any statistically significant differences between ANA and CAN (p=0.056), and between patients treated in monotherapy compared to the subgroup co-administered with conventional immunosuppressors (p=0.058). On the contrary, significant differences were found between biologic-naive patients and those previously treated with biologic drugs (p=0.038) and when distinguishing according to adverse events (AEs) occurrence (p=0.04). In regression analysis, patients pre-treated with other biologics (HR=3.357 [C.I. 1.341-8.406], p=0.01) and those experiencing AEs (HR=2.970 [C.I. 1.186-7.435], p=0.020) were associated with a higher hazard ratio of IL-1 inhibitors withdrawal. The mean treatment delay was significantly higher among patients discontinuing IL-1 inhibitors (p=0.0002). Conclusions: Our findings suggest an excellent overall DRR for both ANA and CAN that might be further augmented by paying attention to AEs and employing these agents as first-line biologics in the early stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petty, R. E., Southwood, T. R. E., Manners, P. J., Baum, J., Glass, D. N., Goldenberg, J., He, X.-H., Maldonado-Cocco, J. A., Orozco-Alcalá, J., Prieur, A., et al. (2004) · PubMed · Cited by 4,176
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., Brik, R., McCann, L., Kasapcopur, O., Rutkowska-Sak, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205099 · Cited by 713
Self-citationQuartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., Bossuyt, X., Boutten, A., Bienvenu, J., Duquesne, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134254 · Cited by 558
Self-citationNigrovic, P. A., Mannion, M., Prince, F. H. M., Zeft, A., Rabinovich, C. E., van Rossum, M. A. J., Cortis, E., Pardeo, M., Miettunen, P. M., Janow, G., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30128 · Cited by 463
Self-citationMinoia, F., Davì, S., Horne, A., Demirkaya, E., Bovis, F., Li, C., Lehmberg, K., Weitzman, S., Insalaco, A., Wouters, C., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38802 · Cited by 429
Self-citationLequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., Kone-Paut, I., Michel, M., Dernis, E., Khellaf, M., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076034 · Cited by 406
Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions
Mellins, E. D., Macaubas, C., & Grom, A. A. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.68 · Cited by 330
Ringold, S., Weiss, P. F., Beukelman, T., DeWitt, E. M., Ilowite, N. T., Kimura, Y., Laxer, R. M., Lovell, D. J., Nigrovic, P. A., Robinson, A. B., et al. (2013) · Arthritis Care & Research · doi:10.1002/acr.22087 · Cited by 306
Vastert, S. J., de Jager, W., Noordman, B. J., Holzinger, D., Kuis, W., Prakken, B. J., & Wulffraat, N. M. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38296 · Cited by 258
Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?
Nigrovic, P. A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38615 · Cited by 217
Treatment of juvenile idiopathic arthritis: a revolution in care
Stoll, M. L., & Cron, R. Q. (2014) · Pediatric Rheumatology · doi:10.1186/1546-0096-12-13 · Cited by 176
Verbsky, J. W., & White, A. J. (2004) · PubMed · Cited by 168
Systemic-onset juvenile idiopathic arthritis
Cimaz, R. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.004 · Cited by 138
Self-citationRusso, R. A. G., & Katsicas, M. M. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090952 · Cited by 83
for the “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology), Sota, J., Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, R., Cimaz, R., et al. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4119-x · Cited by 82
Self-citationA systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner
Rigante, D. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1280396 · Cited by 69
Self-citationBridging the Gap between the Clinician and the Patient with Cryopyrin-Associated Periodic Syndromes
Cantarini, L., Lucherini, O. M., Frediani, B., Brizi, M. G., Bartolomei, B., Cimaz, R., Galeazzi, M., & Rigante, D. (2011) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201102400402 · Cited by 63
Self-citationOtten, M. H., Prince, F. H. M., Anink, J., Cate, R. T., Hoppenreijs, E. P. A. H., Armbrust, W., Koopman-Keemink, Y., van Pelt, P. A., Kamphuis, S. S. M., GORTER, S. L., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201060 · Cited by 61
Pardeo, M., Bracaglia, C., & De Benedetti, F. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.02.002 · Cited by 60
Self-citationFeist, E., Quartier, P., Fautrel, B., Schneider, R., Sfriso, P., Efthimiou, P., Cantarini, L., Lheritier, K., Leon, K., Karyekar, C. S., et al. (2018) · PubMed · Cited by 60
Self-citationHedrich, C. M., Brück, N., Fiebig, B., & Gahr, M. L. (2011) · Rheumatology International · doi:10.1007/s00296-011-2249-4 · Cited by 50
Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience
Pardeo, M., Marafon, D. P., Insalaco, A., Bracaglia, C., Nicolai, R., Messia, V., & Benedetti, F. D. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141567 · Cited by 49
Self-citationRigante, D. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.067 · Cited by 34
Self-citationSystemic Juvenile Idiopathic Arthritis: Diagnosis and Management
Kumar, S. (2016) · The Indian Journal of Pediatrics · doi:10.1007/s12098-016-2060-z · Cited by 27
Investigational drugs for treatment of juvenile idiopathic arthritis
Mauro, A., Rigante, D., & Cimaz, R. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1301929 · Cited by 14
Self-citation
Research works printed but not linked: 3
- Davies, 2017, Mortality rates are increased in patients with systemic juvenile idiopathic arthritis., Arch. Dis. Child., 102, 206, 10.1136/archdischild-2016-311571 · doi:10.1136/archdischild-2016-311571
- Dewoolkar, 2017, Course, outcome and complications in children with systemic onset juvenile idiopathic arthritis., Indian J. Pediatr., 84, 294, 10.1007/s12098-017-2293-5 · doi:10.1007/s12098-017-2293-5
- Tynjälä, 2009, Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis., Ann. Rheum. Dis., 68, 552, 10.1136/ard.2007.087130 · doi:10.1136/ard.2007.087130
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Fregni, F., El-Hagrassy, M. M., Pacheco-Barrios, K., Carvalho, S., Leite, J., Simis, M., Brunelin, J., Nakamura-Palacios, E. M., Marangolo, P., Venkatasubramanian, G., et al. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa051 · Cited by 605
Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions
Mohammad, S., & Thiemermann, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594150 · Cited by 585
Nanoparticle-based drug delivery systems for cancer therapy
Dang, Y., & Guan, J. (2020) · Smart Materials in Medicine · doi:10.1016/j.smaim.2020.04.001 · Cited by 553
Metadata
- Authors
- Sota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M. C., Lopalco, G., La Torre, F., Fabiani, C., Pardeo, M., Olivieri, A. N., Sfriso, P., Salvarani, C., Gaggiano, C., Grosso, S., Bracaglia, C., De Benedetti, F., Rigante, D., & Cantarini, L.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-01-08
- Volume
- 9
- Pages
- 1526-1526
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2909739147
- Cited by
- 616
- References
- 25
- FWCI
- 90.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.